2-[3-(1-acetyl-3-ethyl-azepan-3-yl)-phenoxy]-4-imidazol-1-ylmethyl-benzonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-(1-acetyl-3-ethyl-azepan-3-yl)-phenoxy]-4-imidazol-1-ylmethyl-benzonitrile
• 英文别名: 2-[3-(1-acetyl-3-ethylazepan-3-yl)phenoxy]-4-(imidazol-1-ylmethyl)benzonitrile
• 化学式: C₂₇H₃₀N₄O₂
• 分子量: 442.561
• InChiKey: RPSVZMJVPOGOLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  71.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  己内酰胺 在 2,2,6,6-四甲基哌啶 、 potassium fluoride on basic alumina 、 lithium aluminium tetrahydride 、 正丁基锂 、 18-冠醚-6 、 三溴化硼 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 49.0h， 生成 2-[3-(1-acetyl-3-ethyl-azepan-3-yl)-phenoxy]-4-imidazol-1-ylmethyl-benzonitrile
  参考文献：
  名称：

  双蛋白法呢基转移酶-香叶基香叶基转移酶-I抑制剂可作为潜在的癌症化学治疗剂。

  摘要：

  一系列新的二芳基醚内酰胺已被确定为非常有效的蛋白法呢基转移酶（FTase）和蛋白geranylgeranyltransferase I（GGTase-I）的双重抑制剂，这些酶涉及Ras的烯丙基化。这些化合物之一与FTase之间形成的配合物的结构已通过X射线晶体学确定。这些化合物是第一个被报道在体内抑制重要癌基因Ki-Ras4B异戊二烯化的化合物。不幸的是，足以达到该终点的剂量迅速致死。

  DOI：

  10.1021/jm020587n

文献信息

• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• [EN] A METHOD OF TREATING CANCER<br/>[FR] UNE METHODE POUR LE TRAITEMENT DU CANCER
  申请人：MERCK & CO INC

  公开号：WO2000059930A1

  公开（公告）日：2000-10-12

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is an inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is an inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前尼基蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向哺乳动物施用至少两种治疗剂量，所述治疗剂量从以下组合中选择：一种是PSA共轭物，一种是前尼基蛋白转移酶抑制剂，无论是按顺序或同时施用。本发明还涉及制备这种组合物的方法。
• Inhibitors of prenyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US20020037888A1

  公开（公告）日：2002-03-28

  The present invention is directed to compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

  本发明涉及抑制前醇基-蛋白质转移酶（FTase）和致癌基因蛋白Ras的前醇化的化合物。该发明进一步涉及含有本发明化合物的化疗组合物以及抑制前醇基-蛋白质转移酶和致癌基因蛋白Ras的方法。
• TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR
  申请人：Lansbury, JR. Peter T.

  公开号：US20110294794A1

  公开（公告）日：2011-12-01

  Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

  本发明提供了一种低剂量法尼醇转移酶抑制剂及其制药组合物，用于治疗蛋白病。这些低剂量低于最初设计这些化合物用于肿瘤治疗所使用的剂量。治疗包括向需要治疗的受体中注射治疗有效量的法尼醇转移酶抑制剂，其中该量能够有效抑制参与自噬通路的非Ras FTase底物的法尼酰化，而不会对Ras或其他与肿瘤相关的底物的法尼酰化产生明显影响。按照本发明的治疗方法还可以包括乙酰胆碱酯酶抑制剂、神经营养因子受体激活剂、NMDA拮抗剂、淀粉样沉积抑制剂、抗精神病药物、抗抑郁药物、抗焦虑药物或抗氧化剂。
• METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：EP1744751A2

  公开（公告）日：2007-01-24